BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29746956)

  • 1. Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer.
    Russo Spena C; De Stefano L; Palazzolo S; Salis B; Granchi C; Minutolo F; Tuccinardi T; Fratamico R; Crotti S; D'Aronco S; Agostini M; Corona G; Caligiuri I; Canzonieri V; Rizzolio F
    J Control Release; 2018 Jul; 281():1-10. PubMed ID: 29746956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA Biogenesis is Enhanced by Liposome-Encapsulated Pin1 Inhibitor in Hepatocellular Carcinoma.
    Sun D; Tan S; Xiong Y; Pu W; Li J; Wei W; Huang C; Wei YQ; Peng Y
    Theranostics; 2019; 9(16):4704-4716. PubMed ID: 31367251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.
    Campaner E; Rustighi A; Zannini A; Cristiani A; Piazza S; Ciani Y; Kalid O; Golan G; Baloglu E; Shacham S; Valsasina B; Cucchi U; Pippione AC; Lolli ML; Giabbai B; Storici P; Carloni P; Rossetti G; Benvenuti F; Bello E; D'Incalci M; Cappuzzello E; Rosato A; Del Sal G
    Nat Commun; 2017 Jun; 8():15772. PubMed ID: 28598431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
    Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a potent and selective covalent Pin1 inhibitor.
    Pinch BJ; Doctor ZM; Nabet B; Browne CM; Seo HS; Mohardt ML; Kozono S; Lian X; Manz TD; Chun Y; Kibe S; Zaidman D; Daitchman D; Yeoh ZC; Vangos NE; Geffken EA; Tan L; Ficarro SB; London N; Marto JA; Buratowski S; Dhe-Paganon S; Zhou XZ; Lu KP; Gray NS
    Nat Chem Biol; 2020 Sep; 16(9):979-987. PubMed ID: 32483379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An irreversible inhibitor of peptidyl-prolyl cis/trans isomerase Pin1 and evaluation of cytotoxicity.
    Ieda N; Itoh K; Inoue Y; Izumiya Y; Kawaguchi M; Miyata N; Nakagawa H
    Bioorg Med Chem Lett; 2019 Feb; 29(3):353-356. PubMed ID: 30585173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1).
    Liu L; Zhu R; Li J; Pei Y; Wang S; Xu P; Wang M; Wen Y; Zhang H; Du D; Ding H; Jiang H; Chen K; Zhou B; Yu L; Luo C
    J Med Chem; 2022 Feb; 65(3):2174-2190. PubMed ID: 35089030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Pin1 in the development and treatment of cancer.
    Min SH; Zhou XZ; Lu KP
    Arch Pharm Res; 2016 Dec; 39(12):1609-1620. PubMed ID: 27572155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.
    Lian X; Lin YM; Kozono S; Herbert MK; Li X; Yuan X; Guo J; Guo Y; Tang M; Lin J; Huang Y; Wang B; Qiu C; Tsai CY; Xie J; Gao ZJ; Wu Y; Liu H; Zhou XZ; Lu KP; Chen Y
    J Hematol Oncol; 2018 May; 11(1):73. PubMed ID: 29848341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.
    Yang D; Luo W; Wang J; Zheng M; Liao XH; Zhang N; Lu W; Wang L; Chen AZ; Wu WG; Liu H; Wang SB; Zhou XZ; Lu KP
    J Control Release; 2018 Jan; 269():405-422. PubMed ID: 29170140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a molecular target in breast cancer: a therapeutic perspective of gynecological cancer.
    Kim G; Bhattarai PY; Choi HS
    Arch Pharm Res; 2019 Feb; 42(2):128-139. PubMed ID: 30684192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.
    Liao XH; Zhang AL; Zheng M; Li MQ; Chen CP; Xu H; Chu QS; Yang D; Lu W; Tsai TF; Liu H; Zhou XZ; Lu KP
    Sci Rep; 2017 Mar; 7():43639. PubMed ID: 28262728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.
    Xu M; Cheung CC; Chow C; Lun SW; Cheung ST; Lo KW
    PLoS One; 2016; 11(6):e0156833. PubMed ID: 27258148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.
    Dubiella C; Pinch BJ; Koikawa K; Zaidman D; Poon E; Manz TD; Nabet B; He S; Resnick E; Rogel A; Langer EM; Daniel CJ; Seo HS; Chen Y; Adelmant G; Sharifzadeh S; Ficarro SB; Jamin Y; Martins da Costa B; Zimmerman MW; Lian X; Kibe S; Kozono S; Doctor ZM; Browne CM; Yang A; Stoler-Barak L; Shah RB; Vangos NE; Geffken EA; Oren R; Koide E; Sidi S; Shulman Z; Wang C; Marto JA; Dhe-Paganon S; Look T; Zhou XZ; Lu KP; Sears RC; Chesler L; Gray NS; London N
    Nat Chem Biol; 2021 Sep; 17(9):954-963. PubMed ID: 33972797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Roles of Pin1 in Cancer Development and Progression.
    Han HJ; Choi BY; Surh YJ
    Curr Pharm Des; 2017 Nov; 23(29):4422-4425. PubMed ID: 28671058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways.
    Yan X; Zhu Z; Xu S; Yang LN; Liao XH; Zheng M; Yang D; Wang J; Chen D; Wang L; Liu X; Liu J; Chen RH; Zhou XZ; Lu KP; Liu H
    Sci Rep; 2017 Apr; 7():45915. PubMed ID: 28383568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Prenylated Flavonol Derivative as a Pin1 Inhibitor to Suppress Hepatocellular Carcinoma by Modulating MicroRNA Biogenesis.
    Zheng Y; Pu W; Li J; Shen X; Zhou Q; Fan X; Yang SY; Yu Y; Chen Q; Wang C; Wu X; Peng Y
    Chem Asian J; 2019 Jan; 14(1):130-134. PubMed ID: 30474357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy.
    Zhao B; Zhou B; Shi K; Zhang R; Dong C; Xie D; Tang L; Tian Y; Qian Z; Yang L
    Cancer Sci; 2021 Jun; 112(6):2481-2492. PubMed ID: 33792132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 4,6-bis(benzyloxy)-3-phenylbenzofuran as a novel Pin1 inhibitor to suppress hepatocellular carcinoma via upregulating microRNA biogenesis.
    Fan X; He H; Li J; Luo G; Zheng Y; Zhou JK; He J; Pu W; Zhao Y
    Bioorg Med Chem; 2019 Jun; 27(11):2235-2244. PubMed ID: 31027708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
    Beretta GL; De Cesare M; Albano L; Magnifico A; Carenini N; Corna E; Perego P; Gatti L
    Tumori; 2016; 102(2):144-9. PubMed ID: 26917410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.